Progyny (NASDAQ:PGNY) Reaches New 12-Month Low - Here's What Happened

Key Points

• Progyny hit a new 52-week low, trading as low as $16.28 (last $16.47) on heavy volume of about 1.16 million shares and a market cap near $1.29 billion.
• Analysts maintain a consensus "Moderate Buy" rating with an average price target of $27.91, despite several recent target cuts and mixed buy/hold opinions.
• The company beat its latest quarter estimates (EPS $0.48 vs. $0.38; revenue $318.4M vs. $314.3M) and set FY2026 guidance of $1.83–$1.95 EPS, while insiders have recently sold shares (EVP sold 4,657 shares).

Progyny, Inc. (NASDAQ:PGNY - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $16.28 and last traded at $16.47, with a volume of 1157209 shares traded. The stock had previously closed at $16.60.

Analyst Upgrades and Downgrades

PGNY has been the subject of a number of analyst reports. Jefferies Financial Group reiterated a "buy" rating and set a $30.00 target price on shares of Progyny in a report on Friday, March 6th. Canaccord Genuity Group lowered their price target on Progyny from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Wednesday, March 11th. BTIG Research cut their price objective on Progyny from $35.00 to $30.00 and set a "buy" rating on the stock in a research report on Thursday, March 5th. JPMorgan Chase & Co. set a $35.00 target price on Progyny in a research note on Wednesday, January 21st. Finally, Truist Financial decreased their target price on Progyny from $34.00 to $28.00 and set a "buy" rating for the company in a report on Monday, March 2nd. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Progyny has an average rating of "Moderate Buy" and a consensus price target of $27.91.

Progyny Stock Down 0.8%

The company's fifty day simple moving average is $19.77 and its 200 day simple moving average is $22.17. The firm has a market capitalization of $1.29 billion, a PE ratio of 25.34, a price-to-earnings-growth ratio of 0.96 and a beta of 0.99.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. The firm had revenue of $318.40 million during the quarter, compared to analyst estimates of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The business's revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Equities research analysts forecast that Progyny, Inc. will post 0.6 EPS for the current year.

Insider Buying and Selling

In other news, EVP Allison Swartz sold 4,657 shares of the business's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the sale, the executive vice president owned 89,879 shares in the company, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 7,455 shares of company stock worth $129,515 over the last ninety days. Company insiders own 9.40% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd purchased a new stake in Progyny in the fourth quarter worth about $25,000. Federated Hermes Inc. grew its stake in shares of Progyny by 147.3% in the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company's stock worth $30,000 after buying an additional 819 shares during the last quarter. Hantz Financial Services Inc. increased its position in Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company's stock valued at $43,000 after buying an additional 742 shares in the last quarter. Versant Capital Management Inc increased its position in Progyny by 61.8% during the 3rd quarter. Versant Capital Management Inc now owns 2,340 shares of the company's stock valued at $50,000 after buying an additional 894 shares in the last quarter. Finally, Covestor Ltd raised its stake in Progyny by 164.9% during the third quarter. Covestor Ltd now owns 2,609 shares of the company's stock valued at $56,000 after buying an additional 1,624 shares during the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.